Collecting Duct Na\textsuperscript{+}/K\textsuperscript{+}-ATPase Activity Is Correlated with Urinary Sodium Excretion in Rat Nephrotic Syndromes

GEORGES DESCHÈNES* and ALAIN DOUCET†

*Service de Néphrologie Pédiatrique, Hôpital Armand-Trousseau, Assistance Publique-Hôpitaux de Paris, Paris, France, and †Laboratoire de Biologie Intégrée des Cellules Rénales, Centre National de la Recherche Scientifique Unité de Recherche Associée 1859, Service de Biologie Cellulaire, Commissariat à l’Energie Atomique, Saclay, France.

Abstract. In puromycin aminonucleoside (PAN)-treated nephrotic rats, sodium retention is associated with increased Na\textsuperscript{+}/K\textsuperscript{+}-ATPase activity in the cortical collecting ducts (CCD). This study was undertaken to determine whether stimulation of Na\textsuperscript{+}/K\textsuperscript{+}-ATPase in the CCD is a feature of other experimental nephrotic syndromes, whether it might be responsible for renal sodium retention, and whether it is mediated by increased plasma vasopressin levels or activation of calcineurin. For this purpose, the time courses of urinary excretion of sodium and protein, sodium balance, ascites, and Na\textsuperscript{+}/K\textsuperscript{+}-ATPase activities in microdissected CCD were studied in rats with PAN or adriamycin nephrosis or HgCl\textsubscript{2} nephropathy. The roles of vasopressin and calcineurin in PAN nephrosis were evaluated by measuring these parameters in Brattleboro rats and in rats treated with cyclosporin or tacrolimus. Despite different patterns of changes in urinary sodium and protein excretion in the three nephrotic syndrome models, there was a linear relationship between CCD Na\textsuperscript{+}/K\textsuperscript{+}-ATPase activities and sodium excretion in all three cases. The results also indicated that there was no correlation between proteinuria and sodium retention, but ascites was present only when proteinuria was associated with marked reduction of sodium excretion. Finally, the lack of vasopressin in Brattleboro rats or the inhibition of calcineurin by administration of either cyclosporin or tacrolimus did not prevent development of the nephrotic syndrome in PAN-treated rats or stimulation of CCD Na\textsuperscript{+}/K\textsuperscript{+}-ATPase. It is concluded that stimulation of Na\textsuperscript{+}/K\textsuperscript{+}-ATPase in the CCD of nephrotic rats might be responsible for sodium retention and that this phenomenon is independent of proteinuria and vasopressin and calcineurin activities.

Nephrotic syndromes may develop in many mammalian species as a result of primary diseases such as minimal change disease in human patients, inflammatory diseases such as membranous nephropathy or immune glomerulonephritis in human patients or laboratory animals, or exposure to toxic substances such as adriamycin or puromycin aminonucleoside (PAN) in rats (1–4). In addition to proteinuria and podocyte foot process effacement, development of edema and ascites are permanent features in the majority of models and diseases (3,4). Marked decreases in urinary sodium excretion are common clinical observations in human minimal change disease (5), and decreases in the fractional excretion of sodium are observed in animal models such as PAN nephrosis (6), adriamycin nephrosis (7), immune glomerulonephritis resulting from rabbit anti-rat serum (8), or Heymann nephritis in rats (9).

In vivo micropuncture experiments have shown that the collecting duct is the site of sodium retention in the kidney of PAN nephrotic rats (10). Na\textsuperscript{+}/K\textsuperscript{+}-ATPase activity is significantly enhanced in the cortical collecting ducts (CCD) of rats with PAN nephrosis, during a period with a positive sodium balance (6,11). Therefore, the initial aims of this study were to evaluate whether enhanced Na\textsuperscript{+}/K\textsuperscript{+}-ATPase activity in the CCD is a general feature of experimental nephrotic syndromes and whether this enhanced activity is responsible for decreased urinary sodium excretion. For this purpose, Na\textsuperscript{+}/K\textsuperscript{+}-ATPase activity was measured in CCD during periods of urinary sodium retention in PAN nephrosis and in two other experimental models of the nephrotic syndrome in rats, i.e., adriamycin nephrosis and membranous nephropathy induced by mercury chloride (12,13), and the time course of Na\textsuperscript{+}/K\textsuperscript{+}-ATPase stimulation was correlated with that of decreased urinary sodium excretion during the development of ascites in the early phases of these three experimental nephrotic syndromes. Results suggest that stimulation of Na\textsuperscript{+}/K\textsuperscript{+}-ATPase in CCD is a major molecular mechanism leading to primary sodium retention in all three experimental models of the nephrotic syndrome.

The production of edema and ascites in the nephrotic syndrome was traditionally considered to be the result of a chain of events that included successively decreased oncotic pressure, primary leakage of fluid into the interstitial compartment, hypovolemia, secondary hyperaldosteronism, and decreases in urinary sodium excretion (14). However, this hypovolemia concept, or underfill hypothesis, cannot explain all features of volume regulation and sodium reabsorption in the nephrotic syndrome (15). Hypovolemia is not a universal feature among...
nephrotic patients (5), and hypervolemia has been demonstrated in some animal models of the nephrotic syndrome (16). In addition, the nephrotic syndrome occurs in adrenalectomized rats (6,8). Alternately, the overflow hypothesis now assumes that decreased urinary sodium excretion is a primary tubular disorder in nephrotic syndromes that is independent of low oncotic pressure and is responsible for primary extracellular volume expansion, which leads to secondary leakage of fluid into the interstitium. The second aim of this study was therefore to evaluate the possible roles of factors other than aldosterone, \textit{i.e.}, vasopressin and calcineurin, in the physiopathologic processes of PAN nephrosis and inflammation in the stimulation of collecting duct Na\textsuperscript{+}/K\textsuperscript{+}-ATPase. Vasopressin is known to stimulate Na\textsuperscript{+}/K\textsuperscript{+}-ATPase activity in the CCD (17,18), and plasma levels of vasopressin increase during PAN nephrosis (19,20). Activation of calcineurin also stimulates Na\textsuperscript{+}/K\textsuperscript{+}-ATPase activity in rat CCD (21), and the calcineurin inhibitors cyclosporin and tacrolimus significantly decrease proteinuria in PAN nephrosis (22,23). To determine the roles of vasopressin and calcineurin in sodium retention during PAN nephrosis, we evaluated the effects of PAN in Brattleboro rats, which genetically lack vasopressin secretion, and in Sprague Dawley rats treated with either cyclosporin or tacrolimus. The results demonstrate that PAN-induced nephrosis and stimulation of CCD Na\textsuperscript{+}/K\textsuperscript{+}-ATPase are independent of vasopressin action and calcineurin stimulation.

Materials and Methods

\textbf{Experimental Nephrotic Syndrome Models}  
Male rats (130 to 160 g body wt) of the Sprague Dawley (Iffa-Credo, L’Arbresle, France), Brown Norway (Elevage Janvier, Le Genest-St-Isse, France), Long-Evans (Harlan, Gamnat, France), or Brattleboro (Harlan France) strain were used to develop three experimental nephrotic syndrome models: PAN-induced nephrosis, mercury chloride-induced membranous nephropathy, and adriamycin-induced nephrosis. PAN nephrosis was induced in Sprague Dawley, Long-Evans, and Brattleboro rats by a single intraperitoneal injection of PAN ( Sigma, St. Louis, MO) at a dose of 150 mg/kg body wt, diluted to 15 mg/ml in 0.9\% NaCl. Adriamycin nephrosis was induced in Sprague Dawley rats by a single dose of 7.5 mg/kg body wt adriamycin (Sigma), diluted to 0.75 mg/ml in 0.9\% NaCl and injected into the tail vein. HgCl\textsubscript{2} nephropathy was induced in Brown Norway rats by repeated injections of HgCl\textsubscript{2} (Sigma) at a dose of 1 mg/kg body wt, diluted to 1 mg/ml in 0.9\% NaCl; subcutaneous injections into the abdominal skin were administered on days 0, 2, 4, 7, 9, and 11.

\textbf{Treatment of Rats with Calcineurin Inhibitors}  
Cyclosporin (Novartis) and tacrolimus (Fujiwasa Pharmaceutical Co., Osaka, Japan) were dissolved in DMSO and were continuously delivered for 7 d through osmotic mini-pumps (Alzet 2001; Charles River, St. Aubin-les-Elbeuf, France) that had been implanted subcutaneously under light ether anesthesia. Cyclosporin and tacrolimus were administered at 8 and 4 mg/kg per d, respectively. Plasma concentrations of the two drugs were analyzed by fluorescence polarization immunoassays, using a monoclonal antibody, in total blood samples obtained by retro-ocular puncture throughout the study.

\textbf{Metabolic Studies}  
Animals were housed in individual metabolic cages, starting 2 d before the beginning of the experiments. Nephrotic rats had free access to food and water throughout the study, whereas untreated, pair-fed control animals had free access to water, but each day were given the mean daily intake of the corresponding treated rats. Twenty-four-hour urine samples were collected, under mineral oil, for periods beginning 1 d before the single or first injection (day 0) and lasting for 12 d for PAN nephrosis, 14 d for HgCl\textsubscript{2} nephropathy, and 21 d for adriamycin nephrosis. Urine volume was gravimetrically determined. Blood samples were obtained by retro-ocular puncture every day, except for adriamycin nephrosis, for which collection was restricted to days 0 to 5, 7, 10, 13, 17 to 19, and 21. Food intake was measured every day for evaluation of the net urinary sodium balance and determination of the amount of food to be given to the pair-fed rats that constituted the control group for each nephrotic syndrome model. Plasma and urinary sodium and creatinine and urinary protein concentrations were measured with an automatic analyzer (Hitachi 911; Boehringer Mannheim) by indirect potentiometry with ion-selective electrodes and colorimetric reactions, using pyrogallol red (for protein assays) and the Jaffé reagent (for creatinine assays). Ascites volumes were measured after euthanasia by moistening and weighing an absorbent paper.

The daily urinary sodium balance was calculated as the difference between dietary sodium intake and urinary sodium excretion in the 24-h observation periods. To circumvent pitfalls resulting from variations in sodium concentrations attributable to dilution of the final urine samples and to artificial errors in collection, urinary sodium excretion was calculated either as fractional excretion or as a function of urinary creatinine excretion (in mmol sodium/ml creatinine). Because fractional sodium excretion was linearly correlated with the urinary sodium/creatinine concentrations in the three experimental models (PAN nephrosis, \(r = 0.98, 46\) measurements from four animals, \(P < 0.0001\); HgCl\textsubscript{2} nephropathy, \(r = 0.91, 51\) measurements from four animals, \(P < 0.0001\); adriamycin nephrosis, \(r = 0.91, 55\) measurements from five animals, \(P < 0.0001\)), data are presented as urinary sodium/urinary creatinine concentrations. Similarly, protein excretion was expressed as a function of creatinine excretion (g/mmol creatinine).

The variations in GFR were evaluated in the three models by assessment of creatinine clearance. In PAN nephrosis, GFR decreased slightly at the beginning of the treatment and reached a minimum on day 5 (0.26 ± 0.03 versus 0.66 ± 0.20 ml/min on day 0, mean ± SD, \(P < 0.05\) ) before returning to control levels. In mercury chloride nephropathy, a brief period of acute renal failure occurred on days 2 and 3 (creatinine clearance on day 0, 0.64 ± 0.16 ml/min; day 2, 0.10 ± 0.07 ml/min; day 3, 0.21 ± 0.11 ml/min; mean ± SD); thereafter, GFR returned to control levels throughout the study. GFR did not change during the 21 d of follow-up monitoring of adriamycin-treated rats.

\textbf{Microdissection of CCD and Determination of Na\textsuperscript{+}/K\textsuperscript{+}-ATPase Hydrolytic Activity}  
Na\textsuperscript{+}/K\textsuperscript{+}-ATPase activity was determined by a radiochemical assay based on the measurement of phosphate released from \([\gamma\textsuperscript{32}P]\)ATP by the ATPase contained in pools of 2 to 5 mm of CCD. Rats were anesthetized (pentobarbital, 50 mg/kg body wt), and the left kidney of each rat was infused with 5 ml of infusion solution (see composition below), containing 12 mg of collagenase (from Clostridium histolyticum, 0.75 U/mg; Serva, Heidelberg, Germany), through an aortic catheter. The kidney was then removed and sliced into small pyra-
mids, which were incubated at 30°C for 20 min. CCD were dissected in the dissection solution at 0 to 4°C, under stereoscopic observation. The CCD were identified by morphologic and topographic criteria. The infusion solution contained 120 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 1 mM ethylenediaminetetra-acetic acid, 100 mM Tris-HCl, 10 mM Na₃-ATP, and tracer amounts of [γ-³²P]ATP (10 Ci/mmol; Du Pont de Nemours, Boston, MA). For measurement of basal Mg²⁺-ATPase activity, NaCl and KCl were omitted, the Tris-HCl concentration was 150 mM, and 1 mM ouabain was added. The pH of both solutions was adjusted to 7.4.

Incubation was stopped by the addition of 300 μl of an ice-cold 15% (w/v) suspension of activated charcoal. The microplate was centrifuged (2000 rpm for 3 min), and 100 μl of each supernatant was transferred to a 96-well flat-bottomed plastic microplate and were photographed for determination of the total tubular length of each pool. Two microliters of 10 mM Tris-HCl were added to each well, and the microplate was subjected to a freezing/thawing step for permeabilization of the cell membranes.

After addition of 10 μl of ATPase assay solution to each well, the radioactivity in each well was determined by Cerenkov counting (1450 Microbeta Trilux; Wallac). Total ATPase activity per millimeter tubular length was calculated as the difference between the mean total ATPase activity and the mean Mg²⁺-ATPase activity and is expressed as picomoles per millimeter per hour. Data represent means and SD from at least four animals, except as otherwise indicated in the figure legends.

This semiautomated method, derived from that of Doucet et al. (24), facilitated the study of the large populations of animals required for these kinetic experiments in the three models of nephrotic syndrome. Because of the lower thermic conductance of plastic microplates compared with the aluminum plates used in the original method, the measured Na⁺/K⁺-ATPase activities were approximately one-half of those reported previously. Because ATPase activities were determined for pools of four to six CCD, the intersample biologic variability was greatly reduced. Therefore, although we used triplicate samples (instead of quintuplicate samples, as in the original method) and the activities were lower, the variability among replicates was in the range of 2 to 8% in this study, compared with 15 to 20% reported for the original technique. The linearity of Na⁺/K⁺-ATPase activity as a function of the time of incubation was verified from 5 to 40 min (r = 0.98, P < 0.001).

Results

PAN Nephrosis in Sprague Dawley Rats

Based on the time course of variations in ascites (Figure 1B), the acute phase of PAN nephrosis can be divided into two periods. The first period, from day 0 to day 8, was marked by the onset of ascites on day 4, a dramatic increase on day 6 (15.2 ± 6 g), and stable levels to day 8. Urinary sodium excretion increased transiently 1 d after PAN injection (34.4 ± 6.7 versus 26.7 ± 1.2 mmol/mmol creatinine on day 0, P < 0.01) (Figure 1A). (Urinary sodium excretion also increased in control rats that received the same amount of 0.9% NaCl. However, this increase was less important and was not statistically significant [26.4 ± 2.9 versus 19.9 ± 2.2 mmol/mmol creatinine, n = 4, NS]). Excretion then decreased to an intermediate level (7.5 ± 5.9 to 9 ± 3 mmol/mmol creatinine) on days 2 to 4 and reached a very low level (1.0 ± 0.1 to 4.0 ± 2.4 mmol/mmol creatinine) on days 5 to 8 after PAN administration. This decrease was not related to any decrease in food intake, because pair-fed control rats exhibited significantly higher urinary sodium excretion on days 2 to 8. Consequently, PAN-treated rats displayed a positive sodium balance (+565 ± 234 to +1144 ± 336 μmol/d) during this period of decreased sodium excretion (Figure 1B). Na⁺/K⁺-ATPase activity in the CCD varied conversely with urinary sodium excretion; activity decreased on day 1 and increased on days 2 to 8 (Figure 1C). Proteinuria increased on day 5, 3 d after the reduction of urinary sodium excretion, and reached a plateau on day 6, when urinary sodium excretion was at its nadir.

The second period, from days 9 to 12, was marked by partial recovery from ascites on day 10; recovery was complete on day 12, despite persistent high proteinuria. During this period, urinary sodium excretion increased progressively toward higher than basal levels from day 9 to day 11, so that the sodium balance was negative on days 10 and 11, before returning to basal values (with equilibrated sodium balance) on day 12. During this period, Na⁺/K⁺-ATPase activity remained high until day 10 and then decreased to basal levels on day 12.

During the first period (days 0 to 8), there was a linear relationship (r = 0.907, P < 0.001) between urinary sodium excretion and Na⁺/K⁺-ATPase activity in CCD (Figure 2). This relationship did not persist during the second period (days 9 to 12) because urinary sodium excretion returned to control levels or even higher values, whereas Na⁺/K⁺-ATPase activity remained high, at least on day 10.

Membranous Nephropathy Induced with Mercury Chloride

Urinary sodium excretion peaked on day 2 after the first injection of HgCl₂ and decreased slightly but significantly (to approximately 15 mmol/mmol creatinine) between days 3 and 7, before returning almost to basal values (day 0) on days 8 to 10 (Figure 3A). These changes, which were not related to variations in food intake since they were not observed in pair-fed animals (Figure 3A), were too moderate to significantly alter the sodium balance (Figure 3B). During this initial period, animals exhibited no ascites (Figure 3B) and protein-
uria remained undetectable or very low (Figure 3A). Urinary sodium output then decreased markedly (1.9 to 3.7 mmol/mmol creatinine) on days 12 to 14, at a time when the sodium balance became positive (up to $+1256 \pm 113 \mu mol/d$) and moderate ascites ($3.57 \pm 1.4 g$) was observed (Figure 3B). Again, these changes were not related to alterations in food intake. Moderate proteinuria (compared with that in PAN-treated rats) developed almost concomitantly with this late phase of sodium retention (Figure 3A).

Na\(^+/K^+\)-ATPase activity in CCD was significantly increased during the period of sodium retention, when ascites was present (days 12 to 14) (Figure 3C). Again, there was a
into four subgroups according to urinary sodium excretion (F).

E ( ), and a group of rats studied after the onset of proteinuria and subdivided into three subgroups according to urinary sodium excretion points includes a control group ( ), a group of rats studied before proteinuria ’ senting days 7 and 8 are superimposed. For adriamycin nephrosis, the set of 608 Journal of the American Society of Nephrology J Am Soc Nephrol 11: 604 – 615, 2000 nephrotic syndrome model (days 0, 2, 9, and 11 to 14) (Figure 2).

ATPase activity in CCD and urinary sodium excretion in this two models described previously in that there was large inter-

linear relationship (r = 0.978, P < 0.001) between Na+/K+-ATPase activity in CCD and urinary sodium excretion in this nephrotic syndrome model (days 0, 2, 9, and 11 to 14) (Figure 2).

Adriamycin Nephrosis

The adriamycin model was fundamentally different from the two models described previously in that there was large inter-

individual variability in the time course of drug-induced sodium retention. The mean coefficient of variation for urinary sodium excretion on different days was much higher in adriamycin-treated rats (25 ± 7%, mean ± SD) than in pair-fed animals (10 ± 6%) (Figure 4). As a result, during the 21 d of follow-up monitoring, the mean urinary sodium excretion measured for 12 adriamycin-treated rats was not statistically different from that observed for pair-fed control rats or that measured on day 0 (except on day 3, when excretion was reduced compared with day 0, 13.56 ± 6.04 versus 27.19 ± 4.22 mmol/mmol creatinine, P < 0.001). However, individual analysis of the 12 treated rats indicated that the majority of animals experienced short periods of markedly decreased sodium excretion. Although these periods were not synchronized among the animals, they all occurred on days 2 to 5 and/or days 13 to 21. Between days 2 and 5, eight of the 12 rats exhibited 50 to 80% reductions in urinary sodium excretion (compared with day 0), for a mean period of 1.5 d. And during the second period, eight rats (including six of those that demonstrated sodium retention during the first phase) exhibited 60 to 80% reductions in urinary sodium excretion, for a mean period of 1.5 d. The sodium balance was positive (+729 ± 408 µmol/d) at the time of decreased urinary sodium excretion. Despite the desynchronization in the appearance of sodium retention, all 12 animals developed proteinuria on day 7 and thereafter.

Because of this variability, subsequent analysis of the correlation between sodium excretion and CCD Na+/K+-ATPase activity was also performed on an individual basis. Urine samples were collected for assessment of the level of sodium excretion during the 24 h preceding the measurement of Na+/K+-ATPase activity. Animals were studied on either day 0 (control, n = 6), days 3 to 5 (first period of sodium retention before the onset of proteinuria, n = 21), or days 16 to 21 (second phase of sodium retention, associated with proteinuria of >1 g/mmol creatinine, n = 38). In each of the latter two groups, animals were pooled according to their levels of sodium excretion (≤10, 10 to 15, 15 to 20, and >20 mmol/mmol creatinine), regardless of the time since their adriamycin injections, and the mean Na+/K+-ATPase activity in the CCD of these animals was plotted against the mean sodium excretion. Again, Na+/K+-ATPase activity in the CCD was linearly related to urinary sodium excretion (r = 0.93, P < 0.001) (Figure 2). It is noteworthy that of the 38 proteinuric rats that were euthanized on days 16 to 21 for ATPase measurements, eight exhibited sodium excretion levels of <10 mmol/mmol creatinine at the time of the study. Of these eight animals, five exhibited ascites (3.86 ± 1.89 g) and the other three displayed massive mesenteric edema.

Early Phase of PAN Nephrosis in Long-Evans and Brattleboro Rats

This experimental series was designed for investigation of the possible role of vasopressin in the development of the nephrotic syndrome after PAN administration. For this purpose, we compared the time courses of urinary sodium and protein excretion and Na+/K+-ATPase activities in the CCD of Brattleboro rats (which genetically lack vasopressin) and their
Long-Evans strain controls, in response to PAN injections. Brattleboro rats developed PAN nephrosis, including a full-blown nephrotic syndrome and high-range proteinuria (Figure 5). On day 6, ascites (Brattleboro, 12 ± 1.1 g; Long-Evans, 10.8 ± 2.6 g; n = 5, NS) and stimulation of Na⁺/K⁺-ATPase in the CCD (Brattleboro, 765 ± 111 versus 479 ± 100 pmol/mm per h, P < 0.001; Long-Evans, 872 ± 77 versus 570 ± 205 pmol/mm per h, n = 5, P < 0.05) were similar in
the two strains. However, the appearance of proteinuria in the Brattleboro rats was delayed by 2 d compared with the Long-Evans rats, although proteinuria reached similar levels on day 8. In nephrotic Brattleboro rats, as in Sprague Dawley rats, there was a linear relationship between CCD Na\(^+/\)K\(^+\)-ATPase activities and urinary sodium excretion measured on days 0, 1, 3, and 6 (\(r = 0.98, P < 0.05\)) (Figure 5).

Effects of Calcineurin Inhibitors on the Early Phase of PAN Nephrosis in Sprague Dawley Rats

PAN-induced changes in urinary sodium excretion and proteinuria were kinetically and quantitatively similar in normal rats and rats treated with cyclosporin or tacrolimus at therapeutic levels (Figure 6). On day 6, Na\(^+/\)K\(^+\)-ATPase activities in CCD were significantly stimulated in cyclosporin-treated, PAN-treated rats (726 ± 75 pmol/mm per h, \(n = 3, P < 0.01\)) and tacrolimus-treated, PAN-treated rats (729 ± 197 pmol/mm per h, \(n = 3, P < 0.01\)) compared with control animals (401 ± 62 pmol/mm per h, \(n = 6\)), and were not different from those of PAN rats that had not been treated with cyclosporin or tacrolimus (805 ± 126 pmol/mm per h, \(n = 6\)).

Discussion

PAN and adriamycin are toxic agents that induce experimental nephrotic syndromes without glomerular inflammatory lesions or Ig deposits (1,2). Mercury chloride induces a systemic autoimmune disease that includes membranous nephropathy with IgG deposits. This nephropathy is responsible for the development of high-range proteinuria and a full-blown nephrotic syndrome (12). These three experimental models were used to evaluate whether activation of the sodium pump in the CCD might be directly responsible for sodium retention and correlated with ascites formation.

Because the daily time courses of urinary sodium excretion and the relationship of excretion to the appearance of proteinuria and ascites in these three models of nephrotic syndrome were not, or were only partially, described in the literature (6–8,25), we performed a systematic study of the time courses of these parameters. Our results indicated that the time courses and profiles of changes in urinary sodium excretion were different in the three models. Paradoxically, urinary sodium excretion increased on day 1 (PAN nephrosis) or day 2 (HgCl\(_2\) nephropathy) after the first exposure to the toxic agent. These increases cannot be accounted for by the volume of isotonic sodium chloride solution used as the solvent for drug administration, because: (1) the increases were quantitatively similar in the two models, although the PAN-treated rats received a 10-fold greater volume of sodium chloride; (2) the increases were observed only after the first, and not after subsequent injections of HgCl\(_2\); and (3) the increases in urinary sodium excretion were much smaller for control rats given injections of the same amount of saline solution. Instead, the increases likely result from toxic effects on renal tubules and sodium handling, because Na\(^+/\)K\(^+\)-ATPase activities in the CCD were reduced on those days. With respect to urinary sodium excretion, the three models differed both quantitatively and kinetically. At the peak, sodium excretion was reduced by approximately 95% in PAN nephrosis and approximately 90% in HgCl\(_2\) nephrop-
athy but only by approximately 80% in adriamycin nephrosis. These peaks lasted several days in the PAN (days 2 to 8) and 
HgCl₂ (days 12 to 14) models, whereas they were transient 
(mean duration, 1.5 d) in the adriamycin model (occurring at 
any time during the day 2 to 6 and/or day 13 to 21 periods).
This latter observation suggests that the three drugs have 
different pharmacokinetic properties and that rats exhibit dif-
ferent susceptibilities to adriamycin, with respect to sodium 
reabsorption.

In the three models, proteinuria appeared after 5 to 9 d and 
protein levels remained elevated (although at different levels in 
different models) throughout the periods studied. However, the 
experimental models differed in the temporal relationship be-
tween decreased tubular sodium reabsorption and proteinuria. 
Proteinuria appeared 2 d after the onset of decreased urinary 
sodium excretion in PAN nephrosis and concomitantly with the 
marked decreases in sodium excretion in HgCl₂ nephropathy.
In adriamycin nephrosis, brief peaks of sodium retention oc-
curred randomly between days 13 and 21, whereas proteinuria 
was steadily present after day 7 and plateaued after day 15. In 
both PAN and adriamycin nephrosis, the appearance of pro-
teinuria did not influence the course of urinary sodium excre-
tion. In addition, despite significant differences in the patterns 
of proteinuria between Brattleboro and Long-Evans rats, the 
changes in urinary sodium excretion induced by PAN admin-
istration were similar, with respect to time courses and extents, 
in the two strains. Such dissociation between proteinuria and 
renal sodium retention has also been observed in chronic 
Heymann nephritis and chronic serum sickness (26). These 
results support the hypothesis that the reduction of urinary 
sodium excretion may be independent of the development of 
proteinuria and may be attributable to a tubular disorder inde-
pendent of glomerular events.

Interestingly, in all three models, the formation of ascites 
required the association of proteinuria and marked decreases in 
sodium excretion. In PAN nephrosis, ascites appeared 
at the same time as proteinuria, i.e., at a time when the sodium 
balance had been markedly positive for several days. In the 
mercury chloride model, ascites appeared during the period 
associated with proteinuria and reduction of urinary sodium 
excretion and subsided when urinary sodium excretion re-
turned to basal levels, despite persistent high-range proteinuria.
In adriamycin nephrosis, none of the rats with low urinary 
sodium excretion in the period preceding proteinuria (days 2 to 
6) exhibited ascites, and only those with markedly decreased 
sodium excretion in the period associated with proteinuria 
(days 13 to 21) developed ascites (or at least massive edema). 
The volume of ascites was different in the three models; it was 
moderate in the adriamycin and HgCl₂ models and was always 
profuse in PAN nephrosis. This likely explains why ascites 
resorption required several days after restoration of high uri-
nary sodium output in the PAN model.
Several studies suggested that sodium retention in nephrotic syndromes is independent of alterations in GFR and originates in the distal portions of nephrons. The following findings suggest that the reduction of GFR reported in several studies (for either nephrotic patients or animal models) does not contribute to impaired sodium excretion: (1) the nephrotic syndrome has been reported for several patients with normal or high GFR (5,27,28), and (2) administration of either atrial natriuretic peptide (ANP) to PAN nephrotic rats (29) or saralasin to rats with unilateral PAN nephrosis (10) failed to increase urinary sodium excretion, despite significant increases in GFR. In vitro micropuncture studies in rats with nephrotic syndrome attributable to immune glomerulonephritis (9) or PAN-induced nephrosis (10) supported the collecting duct origin of sodium retention, because they demonstrated that: (1) the absolute reabsorption of sodium along the accessible proximal tubule is reduced in parallel with the GFR in experimental nephrotic syndromes (9,10,30,31) (clinical studies also demonstrated decreased proximal sodium reabsorption in nephrotic patients [(32,33)], so that sodium delivery to the loop of Henle remains normal, and (2) sodium reabsorption along the loop of Henle and the distal convoluted tubule accessible to micropuncture is normal (9,10,34), and the delivery of sodium to the collecting duct is normal (10). Therefore, decreased urinary sodium excretion results from increased reabsorption beyond the last accessible micropuncture site of the distal convoluted tubule, most likely in the collecting duct. In addition, treatment with bromoethylamine hydrobromide, which produces severe functional damage to inner medullary collecting ducts (IMCD) and salt wasting, does not prevent sodium retention in response to PAN, a finding that restrains the location of renal sodium retention to the CCD and/or outer medullary collecting ducts in this model (25). This hypothesis supposes that the IMCD do not compensate for the sodium imbalance originating in the CCD. Resistance of the IMCD, in particular to the natriuretic action of ANP, has been documented in the literature. As expected, the levels of ANP are increased in adriamycin and PAN nephrosis (16,29) and in nephrotic patients (35). However, both the sensitivity to ANP and the magnitude of the natriuretic and diuretic responses to ANP are reduced in rats with PAN (29) and adriamycin nephrosis (16) and in human patients with idiopathic nephrotic syndrome (35,36). This resistance, which occurs after ANP binding to its receptors in the collecting duct (16), results from the activation of a phosphodiesterase responsible for the catabolism of cGMP, the second messenger of ANP (37). Impairment of the ANP response in the IMCD could account in part for blunted volume expansion natriuresis in response to a sodium load but, in the absence of any dietary alterations, it cannot represent the only mechanism for primary sodium retention. A combination of these results and our own findings on the stimulation of the Na\(^+\)/K\(^+\)-ATPase in the CCD provides a better explanation. 

\(\text{Na}^+/\text{K}^+\)-ATPase hydrolytic activity and transport capacity are increased on day 7 in the CCD of PAN nephrotic rats (6,11)
but not in the cortical thick ascending limb of Henle’s loop (6) or in the outer medullary collecting duct (data not shown). The results presented here extend these observations to other nephrotic syndrome models, because they demonstrated that Na\(^{+}/K\(^{+}\)-ATPase activity in the CCD was steadily stimulated at each phase of reduction of urinary sodium excretion in the three experimental models and that there was a linear relationship between Na\(^{+}/K\(^{+}\)-ATPase activities in the CCD and urinary sodium excretion before and during the formation of ascites. In the CCD, sodium reabsorption occurs through a two-step mechanism, including primary active pumping of sodium out of the cells by basolateral Na\(^{+}/K\(^{+}\)-ATPase and secondary passive luminal entry of sodium via epithelial sodium channels. Under normal conditions, apical sodium entry is the rate-limiting step for the entire process, because it defines the intracellular sodium concentration and thus the intrinsic rate of Na\(^{+}/K\(^{+}\)-ATPase pumping (38,39). The close correlation between CCD Na\(^{+}/K\(^{+}\)-ATPase activity, as determined in vitro under \(V_{\text{m}}\) conditions, and the final sodium excretion in urine suggests that Na\(^{+}/K\(^{+}\)-ATPase in the CCD becomes rate-limiting for renal sodium handling in nephrotic syndromes. This assumes a dysregulation of epithelial sodium channels. Functional and immunohistologic studies of epithelial sodium channels remain to be performed in PAN nephrosis, as in other nephrotic syndrome models.

The observation that stimulation of Na\(^{+}/K\(^{+}\)-ATPase in the CCD is responsible for sodium retention in three nephrotic syndrome models, involving different toxic agents and different histologic types of glomerular lesions, suggests that this stimulation may be involved in other nephrotic syndrome conditions, including minimal change disease and membranous nephropathy in human patients. Stimulation of Na\(^{+}/K\(^{+}\)-ATPase in the CCD of nephrotic rats could result from dysregulation of any of its known regulators, including aldosterone (40), calcineurin (21), and vasopressin (17). The role of aldosterone in sodium retention in the nephrotic syndrome has been extensively debated since the hypovolemia concept was proposed to explain this disease (14). Such a role was supported by indirect evidence, including: (1) elevated plasma renin and aldosterone levels in children with idiopathic nephrotic syndrome with edema and symptoms of hypovolemia (5) and in rats with PAN nephrosis (8,41–44); (2) a negative correlation between urinary sodium excretion and free urinary aldosterone in nephrotic patients, regardless of dietary sodium content (45–47); and (3) a partial ability of spironolactone to increase urinary sodium excretion in nephrotic patients (48) and PAN nephrotic rats (42). However, many more direct results dispute the hypovolemia concept and argue against a major role of aldosterone, namely: (1) sodium retention and edema may occur in nephrotic patients with normal blood volume and normal aldosterone levels (5,28,49); (2) ascites and edema occur in rats with nephrosis attributable to rabbit anti-rat kidney serum injection, without elevated blood aldosterone levels (8); (3) inhibition of angiotensin-converting enzyme by captopril failed to induce natriuresis in nephrotic patients (50) and in rats with PAN nephrosis (44), despite decreased aldosterone levels; (4) sodium retention was observed only in the affected proteinuric kidney in rats with unilateral models of PAN nephrosis (10) and adriamycin nephrosis (16); and (5) a full-blown nephrotic syndrome occurs in adenoelectomized rats after administration of either PAN or rabbit anti-rat kidney serum (8). Finally, in their seminal work on PAN nephrosis, Vogt and Favre (6) demonstrated that the sodium retention profiles and CCD Na\(^{+}/K\(^{+}\)-ATPase stimulation were similar in normal and adenoelectomized rats. These findings allowed us to conclude that aldosterone is not involved, in a determining way, in renal sodium retention in nephrotic patients and animals and cannot be the effector for the stimulation of CCD Na\(^{+}/K\(^{+}\)-ATPase in animal models of the nephrotic syndrome.

Calcineurin is a calcium/calmodulin-dependent serine-threonine phosphatase that is involved in major cell regulation, including T cell activation. Tacrolimus and cyclosporin, two inhibitors of calcineurin that are used as immunosuppressive drugs, inhibit Na\(^{+}/K\(^{+}\)-ATPase in the CCD by 90% (51) and 40% (21,51), respectively. These effects are mediated by the inhibition of calcineurin activity, because rapamycin and SDZ220-384, which bind to calcineurin (through immunophilins) without inhibiting its activity, do not affect Na\(^{+}/K\(^{+}\)-ATPase activity. Taken together, these findings suggest that calcineurin produces basal activation of Na\(^{+}/K\(^{+}\)-ATPase and thus could be involved in the regulation of urinary sodium excretion. On the other hand, cyclosporin and tacrolimus significantly reduce proteinuria during the plateau period of PAN nephrosis (22,23). The effects of these compounds on urinary sodium excretion during the early phase of the disease had not been studied. Our results indicated that continuous delivery of cyclosporin or tacrolimus by a subcutaneous route, yielding routine therapeutic levels, slightly (but not statistically significantly) reduced proteinuria but did not modify the alterations of urinary sodium excretion induced by PAN administration. In addition, neither cyclosporin nor tacrolimus prevented the stimulation of CCD Na\(^{+}/K\(^{+}\)-ATPase activity that was observed on day 6 after PAN injection. This rules out a major contribution of calcineurin dysregulation in PAN-induced sodium retention.

Chronic administration of vasopressin increases Na\(^{+}/K\(^{+}\)-ATPase activity in the CCD of both Sprague Dawley and Brattleboro rats, whereas it has no significant effect in the outer medullary collecting ducts (17,18). In vitro exposure to vasopressin also stimulates Na\(^{+}/K\(^{+}\)-ATPase activity in the CCD (52). Because the expression of vasopressin mRNA in the hypothalamus and plasma levels of vasopressin are increased during the early phase of PAN nephrosis (19,20), we evaluated the possible role of vasopressin in urinary sodium retention and tubular Na\(^{+}/K\(^{+}\)-ATPase stimulation in PAN nephrosis. Our results with Brattleboro rats, which lack vasopressin secretion, demonstrated that vasopressin is not essential for the development of PAN nephrosis (including sodium retention, proteinuria, and ascites). Na\(^{+}/K\(^{+}\)-ATPase activity was stimulated to the same extents in the CCD of Brattleboro and Long-Evans rats 6 d after PAN administration. That increase in Na\(^{+}/K\(^{+}\)-ATPase activities in the CCD of PAN-treated rats is associated with decreased amounts of Na\(^{+}/K\(^{+}\)-ATPase at the CCD cell surface (11) and suggests posttranscriptional stimulation of the
pump. Our findings on calcineurin and vasopressin allow us to exclude contributions of phosphatase-2B and protein kinase A to this stimulation.

In summary, this study describes the temporal relationships among urinary sodium excretion, sodium balance, proteinuria, ascites, and Na\(^{+/K^{+}}\)-ATPase activities in CCD in three experimental models of the nephrotic syndrome in rats. This study demonstrates that: (1) sodium retention and proteinuria follow independent courses, (2) ascites appears only when proteinuria is associated with marked sodium retention, and (3) Na\(^{+/K^{+}}\)-ATPase activities in the CCD are closely correlated with urinary sodium excretion during the early periods of sodium retention. Our results also demonstrate that the PAN-induced nephrotic syndrome is independent of vasopressin and calcineurin activity. It is concluded that dysregulation of Na\(^{+/K^{+}}\)-ATPase in the CCD is a major factor in primary renal sodium retention in the nephrotic syndrome. Additional studies on the molecular mechanisms underlying this stimulation of Na\(^{+/K^{+}}\)-ATPase could facilitate elucidation of the pathways responsible for the tubular and glomerular disorders in the nephrotic syndrome.

**Acknowledgments**

This work was supported by grants from the Délégation à la Recherche Clinique de l’Assistance Publique-Hôpitaux de Paris and the Centre National de la Recherche Scientifique (PRA 96002). We are grateful to Pr. P. Druet for help in developing the HgCl\(_2\) model of the nephrotic syndrome. In: The Nephrotic Syndrome, edited by Cameron S, Glassock R, New York, Marcel Dekker, 1988, pp 89–162.

**References**

25. Keeler R: Chemical medullectomy does not prevent sodium


